Rating Change
UBS analysts initiated coverage on Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) with a Buy rating on July 02, 2026.
new coverageNASDAQ:CRNX
UBS Initiates Coverage on Crinetics Pharmaceuticals, Inc. (CRNX) with Buy
Rating Change UBS analysts initiated coverage on Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) with a Buy rating on July 02, 2026. Market Context Crinetics Pharmaceuticals, Inc.
Market Context
Crinetics Pharmaceuticals, Inc. operates in the Healthcare sector. The stock currently trades at $42.23 with a market capitalization of $4.7B.
Analyst coverage from UBS provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Crinetics Pharmaceuticals, Inc..
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for Crinetics Pharmaceuticals, Inc.
Among the 10 most recent ratings: 10 Buy, 0 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Jul 02, 2026 | UBS | Buy | N/A |
| Jun 15, 2026 | HC Wainwright & Co. | Buy | N/A |
| Jun 11, 2026 | Citizens | Market Outperform | N/A |
| May 15, 2026 | Evercore ISI Group | Outperform | N/A |
| May 11, 2026 | Oppenheimer | Outperform | N/A |
Related Tools: Analyst Ratings Dashboard | View CRNX Stock Page
Frequently Asked Questions
What does a Buy rating mean for CRNX?
A Buy rating from UBS reflects the analyst's outlook on Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the CRNX forecast page.